GWPH - GW Pharmaceuticals up 6.4% on Q3 beat

GW Pharmaceuticals (GWPH) Q3 results:Revenue: $137.05M (+50.7% Y/Y) vs consensus of $125.97M; Epidiolex U.S. sales: $121.6M.Net loss: ($12.2M) (-11.6%); loss/share: ($0.03) (-25.0%) vs consensus of ($0.06).Cash flow ops: ($33.31M) (-69.0%).Epidiolex for seizures associated with TSC launched in the U.S.Recruitment in Phase 3 of Nabiximols development program in MS spasticity trial under way.Active recruitment started in Phase 2b trial for schizophrenia ((GWP42003)).CBD formulation Phase 2 study in autism, expected to commence in Q1 2021.Shares up 6.4% PM.Previously: GW Pharmaceuticals EPS beats by $0.02, beats on revenue (Nov.03).

For further details see:

GW Pharmaceuticals up 6.4% on Q3 beat